Salute e Benessere

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEWyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectivelyBasel, May 22, 2024– Sandoz, the...
Nasdaq GlobeNewswire
22/05/2024

Novo Nordisk Foundation and Technical University of Denmark press release…

Research has already shown associations between several gut bacteria or metabolites – substances produced by microbes – and CMD. In Phase 1, the initiative will therefore focus on collaborative research projects that investigate the specific effects of these bacteria or metabolites and advance understanding on how microbiome interventions could reduce the risk of CMD or help manage it. This phase will run from 2024-2028. Research has already shown associations between several gut bacteria or...
PR Newswire
22/05/2024

Press news: Sequana Medical announces positive outcome of Day 100 meeting with…

PRESS RELEASE: REGULATED INFORMATION – INSIDE INFORMATION 22 MAY 2024, 07:00 CEST Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®Positive and collaborative meeting with FDAPMA substantive review complete; No further new questions on clinical or pre-clinical dataFDA Advisory Panel no longer expectedFDA Marketing Approval now anticipated in Q1 2025Planned US commercial launch remains H2 2025 ...
Nasdaq GlobeNewswire
22/05/2024

Deenova enters Belgian market with tender win at AZ Saint Lucas Hospital

Deenova, the European leader in pharmacy automation, is thrilled to announce its successful tender win atAZ Saint Lucas Hospitalin Brugge, facilitated by its business partner,Robapharma. This milestone marksDeenova 's entry into the Belgian market and underscores its ongoing commitment to international expansion.Deenovais now present in over 100 hospitals across nine European countries. The collaboration withAZ Saint Lucas HospitalexemplifiesDeenova 's dedication to...
Nasdaq GlobeNewswire
22/05/2024

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and…

COPENHAGEN, Denmark, May 21, 2024– Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which...
Nasdaq GlobeNewswire
21/05/2024

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a…

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and...
Nasdaq GlobeNewswire
21/05/2024

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration…

Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorship of the ongoing Phase 3 pivotal trial in head and neck cancer to begin preparations for potentially positive trial results and subsequent stepsAlignment to Phase 3 head and neck cancer study modifications designed to optimize the regulatory pathway, including intended removal of the now...
Nasdaq GlobeNewswire
21/05/2024

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain

The meeting with the FDA has been set forJuly 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. "We are very pleased with this crucial step towards launching our IND program for LPT-CBD inthe United States," commentedIris Bincovich CEO of Innocan Pharma."This upcoming...
PR Newswire
21/05/2024

Inventiva reports 2024 First Quarter Financial Information¹ and provides a…

Cash and cash equivalents at €11.0 million, short-term 2deposits at €0.1million, and long-term deposit at €19.1 million 3as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively.The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of the current protocol, based on the pre-planned review of interim safety data of more than 900 patients randomized in the main and...
Nasdaq GlobeNewswire
21/05/2024

Cancer Biomarkers Market Size to Grow USD 42170 Million by 2030 at a CAGR of…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-5B8063/Global_Cancer_Biomarker_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-5B8063/Global_Cancer_Biomarker_Market Major Factors Driving the Growth of Cancer Biomarkers Market: Precision medicine and tailored therapeutic advancements have a major role in driving the growth of the cancer biomarker market. With the growing knowledge of the molecular and genetic causes of cancer,...
PR Newswire
21/05/2024

TRANSFORMING LIVER HEALTH: ECHOSENS NEXT-GENERATION FIBROSCAN® NOW AVAILABLE…

Laurent Sandrin, founder and Chief Science & Innovation Officer of Echosens, underscores the crucial role of healthcare professionals in increasing screening rates, with three in 10 people globally at risk for liver disease. "Given the projected surge in liver disease cases, it is imperative to bolster screening rates for early detection. Our next-generation FibroScan®, featuring our patented Guided VCTE™ technology, is designed to be an indispensable and efficient tool for both…
PR Newswire
21/05/2024

ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and…

Nature Medicine published Up-LIFT pivotal trial results Company will discuss pivotal trial results during webcast this week with company leaders and study principal investigators and participants EINDHOVEN, the Netherlands, May21, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that...
Nasdaq GlobeNewswire
21/05/2024

Pharming Group reports on results of the 2024 Annual General Meeting of…

Leiden, the Netherlands, May 21, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals...
Nasdaq GlobeNewswire
21/05/2024

Genmab Completes Acquisition of ProfoundBio

Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cashAcquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate technology platforms COPENHAGEN, Denmark; May 21, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company...
Nasdaq GlobeNewswire
21/05/2024

IVD Quality Control Market to be Worth $2.28 Billion by 2031 - Exclusive Report…

Quality controls for in vitro diagnostics consist of liquid or lyophilized samples containing a predetermined amount of the target analyte. These controls are utilized in laboratory settings to confirm the reliability and accuracy of test results in an in vitro environment. Adhering to quality control and external quality assurance principles is crucial for effectively managing clinical laboratories. By implementing these processes proficiently, the potential risks to patients are minimized, and…
PR Newswire
21/05/2024

Microfluidic Immunoassay Market to be Worth $1.59 Billion by 2031 - Exclusive…

Microfluidic immunoassay or lab-on-a-chip consists of miniaturization of conventional laboratory operations, including reagent loading, reaction, separation, and detection on the microchip. Traditional immunoassays depend on large and costly equipment and skilled professionals, with low sensitivity, complex operation, long assay time, and expensive reagents. Furthermore, with the increasing demand for real-time detection in clinical diagnostics, the need for highly sensitive, portable, enhanced…
PR Newswire
21/05/2024

Sequencing Kits Market to be Worth $25.29 Billion by 2031 - Exclusive Report by…

Sequencing is widely conducted in clinical and research settings. The growth of the sequencing kits market is driven by the increasing prevalence of cancer & genetic disorders, rising healthcare expenditures, increasing funding for research activities, the surge in genome mapping programs, the decreasing costs of sequencing procedures, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, the improving regulatory and…
PR Newswire
21/05/2024

Sample Preparation Market to be Worth $12.77 Billion by 2031 - Exclusive Report…

Sample preparation involves converting the sample into a suitable form that can be further utilized for the analysis, such as chromatographic and spectroscopic analyses. It removes the interfering contamination without the loss of target compounds. Sample preparation involves converting the sample into a suitable form that can be further utilized for the analysis, such as chromatographic and spectroscopic analyses. It removes the interfering contamination without the loss of target compounds...
PR Newswire
21/05/2024

Fitness Equipment Market to Reach $18.4 billion, Globally, by 2033 at 3.02%…

The fitness industry has witnessed a significant transformation with the rise of the Internet of Things (IoT), leading to the evolution of conventional fitness equipment into intelligent counterparts. Through IoT-enabled fitness equipment, workout metrics such as reps, weights lifted, and duration are seamlessly captured and transmitted in real time. This data is then integrated into individual user profiles, offering valuable insights into workout performance and progress. With IoT…
PR Newswire
21/05/2024

LILYSILK Triumphs with Triple Wins in Prestigious 2024 International Beauty and…

Celebrated at Marie Claire UK Celebrated at Marie Claire UK At the Marie Claire UK 2024 Hair Awards, LILYSILK was honored twice, first with theBest Heatless Curlers awardfor its innovativeHeatless Silk Curling Headband and Scrunchie Set, noted for its affordability and effectiveness in creating lasting styles. "As someone who hadn't previously tried this sort of heatless curler tool, it was surprisingly easy to use," said Valeza Bakolli, Junior Shopping Editor at Marie Claire UK...
PR Newswire
21/05/2024

Announcement of The Shaw Laureates 2024

Shrinivas R KulkarniGeorge Ellery Hale Professor of Astronomy and Planetary Science, Division of Physics, Mathematics and Astronomy at the California Institute of Technology, USA Shrinivas R KulkarniGeorge Ellery Hale Professor of Astronomy and Planetary Science, Division of Physics, Mathematics and Astronomy at theCalifornia Institute of Technology, USA for his ground-breaking discoveries about millisecond pulsars, gamma-ray bursts, supernovae, and other variable or transient...
PR Newswire
21/05/2024

StickIt Technologies Announces Investment into Ripco Processing Inc.

The $10,000 unsecured convertible debenture from StickIt, which matures on April 18, 2025, carries a 5% interest rate per annum and is payable at the end of the term. The convertible debenture can be automatically converted into Common Shares at a conversion price of $0.35 per Common Share at the election of the debenture holder. The$10,000unsecured convertible debenture from StickIt, which matures onApril 18, 2025, carries a 5% interest rate per annum and is payable at the end of the term...
PR Newswire
21/05/2024

Philips Foundation 2023 Annual Report: unlocking quality medical services for…

Progress towards Philips Foundation's 2030 target of 100 million lives improved in underserved communities each year17 new initiatives with strategic partners and 4 new investments in health tech enterprises that leverage Philips' expertise in early screening and diagnosis Strategy focused on building local ecosystems that provide reliable, sustainable solutions to healthcare delivery issues in underserved communities Amsterdam, the Netherlands– Philips Foundation , with...
Nasdaq GlobeNewswire
21/05/2024

Ketabon To Present Advancements In At-Home Ketamine Therapy For…

Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® HMNC Brain Health and Develco Pharma , announced today the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach.Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health, will elucidate details on topline results of its Phase 2...
Nasdaq GlobeNewswire
21/05/2024
Altri  Comunicati